<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/bcr568.anc" start="13722" end="13729" sStart="-1" offset="0" sid="null" wn="2" wnkey="success%1:04:00::" annotator="cgozo" text="Attempts by other investigators to confirm these findings were met with various degrees of &lt;b&gt;success&lt;/b&gt;." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/bcr568.anc" start="13722" end="13729" sStart="null" offset="0" sid="null" wn="1" wnkey="success%1:11:00::" annotator="brubin" text="Attempts by other investigators to confirm these findings were met with various degrees of &lt;b&gt;success&lt;/b&gt;." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr568.anc" start="17437" end="17446" sStart="null" offset="94" sid="r11.recommend.v.0542" wn="1" wnkey="recommend%2:32:01::" annotator="anfahmy" text="However, the therapy groups analyzed in the present study are small, and therefore we recommend careful interpretation of the findings." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/bcr568.anc" start="398" end="402" sStart="null" offset="0" sid="null" wn="4" wnkey="rate%1:24:00::" annotator="cgozo" text="A recurrence &lt;b&gt;rate&lt;/b&gt; of 30% may be expected during the first 5 years after diagnosis." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/bcr568.anc" start="398" end="402" sStart="null" offset="0" sid="null" wn="4" wnkey="rate%1:24:00::" annotator="brubin" text="A recurrence &lt;b&gt;rate&lt;/b&gt; of 30% may be expected during the first 5 years after diagnosis." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr568.anc" start="2088" end="2092" sStart="null" offset="355" sid="r7.poor.j.0149" wn="4" wnkey="poor%3:00:02::" annotator="veweser" text="However, studies in recent years have further shown that the c- myc gene participates in most aspects of cellular function, including replication, growth, metabolism, differentiation and apoptosis [ 34 ] . Amplification of the oncogene HER-2 / neu has also been shown to be indicative of poor prognosis in breast cancer." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr568.anc" start="17530" end="17534" sStart="null" offset="27" sid="r7.poor.j.0306" wn="5" wnkey="poor%5:00:00:insufficient:00" annotator="jeneale" text="Higher recurrence rates or poor response to endocrine treatment with tamoxifen in patients with HER-2 / neu -amplified hormone receptor positive tumours, as reported in studies in node-positive or metastatic breast cancer [ 12 15 32 ] , were not observed in the present study." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr568.anc" start="2088" end="2092" sStart="null" offset="355" sid="r7.poor.j.0149" wn="4" wnkey="poor%3:00:02::" annotator="jeneale" text="However, studies in recent years have further shown that the c- myc gene participates in most aspects of cellular function, including replication, growth, metabolism, differentiation and apoptosis [ 34 ] . Amplification of the oncogene HER-2 / neu has also been shown to be indicative of poor prognosis in breast cancer." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr568.anc" start="2381" end="2385" sStart="null" offset="260" sid="r7.poor.j.0387" wn="4" wnkey="poor%3:00:02::" annotator="brubin" text="Studies revealed that the prognostic effect of HER-2 / neu is stronger for survival than for recurrence [ 16 19 20 22 27 29 ] . Furthermore, increased HER-2/neu levels in primary tumours were associated with a poor response to endocrine therapy [ 5 12 15 32 ] ." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr568.anc" start="18466" end="18473" sStart="null" offset="19" sid="r8.number.n.0801" wn="1" wnkey="number%1:07:00::" annotator="veweser" text="Differences in the numbers of recurrences and deaths can be accounted for by the fact that some deaths were not related to tumours." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr568.anc" start="13980" end="13985" sStart="null" offset="249" sid="r8.1.great.j.0844" wn="1" wnkey="great%5:00:01:large:00" annotator="cgozo" text="Some studies claimed that HER-2 / neu status was an independent predictive factor in the case of breast cancer, whereas other studies could not confirm this [ 6 14 16 19 29 30 ] . It is certainly of great interest to the clinician that only two out of five studies including more than 100 patients and with a follow-up period of at least 3 years attributed some prognostic value to HER-2 / neu amplification among patients with NNBC [ 6 7 16 19 28 ] . Almost all of the studies that dealt with HER-2 / neu status and DFS, as well as OS, showed no benefit of this oncogene in the prognosis of NNBC patients." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr568.anc" start="14412" end="14419" sStart="null" offset="681" sid="r11.benefit.n.0358" wn="2" wnkey="benefit%1:07:00::" annotator="vebatchelder" text="Some studies claimed that HER-2 / neu status was an independent predictive factor in the case of breast cancer, whereas other studies could not confirm this [ 6 14 16 19 29 30 ] . It is certainly of great interest to the clinician that only two out of five studies including more than 100 patients and with a follow-up period of at least 3 years attributed some prognostic value to HER-2 / neu amplification among patients with NNBC [ 6 7 16 19 28 ] . Almost all of the studies that dealt with HER-2 / neu status and DFS, as well as OS, showed no benefit of this oncogene in the prognosis of NNBC patients." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr568.anc" start="18105" end="18111" sStart="null" offset="275" sid="r9.appear.v.0657" wn="1" wnkey="appear%2:39:00::" annotator="veweser" text="Although deregulated HER-2 / neu activity can strongly stimulate cytoplasmic signalling pathways, which in turn impinge on c- myc at multiple levels causing its deregulated expression [ 46 ] , this scenario does not appear to be active in NNBC because the recurrence rate of 22 c- myc and HER-2 / neu coamplified patients was only 9%." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr568.anc" start="18666" end="18673" sStart="null" offset="30" sid="r9.appear.v.0261" wn="1" wnkey="appear%2:39:00::" annotator="veweser" text="C- myc amplification appears to represent a prognostic marker with which early recurrence may be predicted in NNBC patients." />
  </sentences>
</list>